New combo therapy targets tough lung cancer in early trial

NCT ID NCT05595460

Ongoing Disease control Sponsor: RayzeBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called RYZ101 added to standard chemotherapy and immunotherapy for people with a specific type of advanced small cell lung cancer that has spread. The main goals are to check safety and find the best dose. About 21 adults who have not had treatment yet will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, EXTENSIVE STAGE

Contacts and locations

Locations

Research Facility

Los Angeles, California, 90024, United States
Research Facility

San Francisco, California, 94158, United States
Research Facility

Jacksonville, Florida, 32224, United States
Research Facility

Miami, Florida, 33136, United States
Research Facility

Orlando, Florida, 32806, United States
Research Facility

Iowa City, Iowa, 52242, United States
Research Facility

Grand Rapids, Michigan, 49503, United States
Research Facility

Rochester, Minnesota, 55905, United States
Research Facility

St Louis, Missouri, 63130, United States
Research Facility

Omaha, Nebraska, 68130, United States
Research Facility

Salt Lake City, Utah, 84112, United States
Research Facility

San Juan, Puerto Rico, 00935, Puerto Rico
Reserach Facility

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.